Nesvacumab

Nesvacumab

Monoclonal antibody
Type	Whole antibody
Source	Human
Target	Angiopoietin 2
Clinical data
ATC code	none
Legal status
Legal status	Investigational
Identifiers
CAS Number	1296818-77-3
IUPHAR/BPS	8457
ChemSpider	none
UNII	WX8293WGLC
KEGG	D10395
Chemical and physical data
Formula	C6440H9966N1722O2008S38
Molar mass	144860.89 g·mol^−1

Nesvacumab is an experimental monoclonal antibody originally designed for the treatment of cancer. It targets the protein angiopoietin 2.^[1][2] As of May 2017^[update], it is in Phase II clinical trials for the treatment of diabetic macular edema.^[3][4]

This drug is being developed by Regeneron Pharmaceuticals.^{[citation needed]}

References

1. Statement On A Nonproprietary Name Adopted By The USAN Council - Nesvacumab, American Medical Association.
2. Hussain RM, Neiweem AE, Kansara V, Harris A, Ciulla TA (October 2019). "Tie-2/Angiopoietin pathway modulation as a therapeutic strategy for retinal disease". Expert Opinion on Investigational Drugs. 28 (10): 861–869. doi:10.1080/13543784.2019.1667333. PMID 31513439.
3. Clinical trial number NCT02713204 for "Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection (ONYX)" at ClinicalTrials.gov
4. Clinical trial number NCT02712008 for "Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema (RUBY)" at ClinicalTrials.gov